A.R.T. Advisors’s Galmed Pharmaceuticals GLMD Stock Holding History

A.R.T. Advisors’s Portfolio GLMD Stock Details GLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-13	Closed	-$107K	–	1547
2018 Q1	$107K	Buy	+13	New	+$152K	﹤0.01%	1347
2015 Q3	–	Sell	-8	Closed	-$118K	–	1440
2015 Q2	$118K	Sell	8 -1	-11%	-$13.9K	﹤0.01%	1348
2015 Q1	$118K	Buy	+9	New	+$108K	﹤0.01%	1301

Other funds holding GLMD

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Ibex Investors Denver, Colorado $194M AUM 23.58% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

MIH

Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

A.R.T. Advisors's GLMD Position: Q2 2018 in Review

A.R.T. Advisors sold out of Galmed Pharmaceuticals (GLMD) in Q2 2018, closing a stake of 13 shares — an estimated $107K sold.

A.R.T. Advisors first reported a position in GLMD in Q1 2015 and held it in 3 quarters. The position peaked at $118K in Q2 2015. 37 funds tracked by Wall St. Rank hold GLMD as of Q2 2018.

A.R.T. Advisors reported no remaining Galmed Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
A.R.T. Advisors sold 13 Galmed Pharmaceuticals shares in Q2 2018, an estimated $107K.
A.R.T. Advisors first reported a position in Galmed Pharmaceuticals in Q1 2015 and held it in 3 quarters.
A.R.T. Advisors's Galmed Pharmaceuticals position peaked at $118K in Q2 2015.
37 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q2 2018.

Based on A.R.T. Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.